Does the media refer more to MNPR or ALMS?

In the previous week, Alumis had 3 more articles in the media than Monopar Therapeutics. MarketBeat recorded 9 mentions for Alumis and 6 mentions for Monopar Therapeutics. Alumis' average media sentiment score of 1.38 beat Monopar Therapeutics' score of 0.61 indicating that Alumis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MNPR or BEAM?

In the previous week, Beam Therapeutics had 6 more articles in the media than Monopar Therapeutics. MarketBeat recorded 12 mentions for Beam Therapeutics and 6 mentions for Monopar Therapeutics. Beam Therapeutics' average media sentiment score of 1.07 beat Monopar Therapeutics' score of 0.61 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MNPR or ZLAB?

In the previous week, Monopar Therapeutics had 2 more articles in the media than Zai Lab. MarketBeat recorded 6 mentions for Monopar Therapeutics and 4 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.70 beat Monopar Therapeutics' score of 0.61 indicating that Zai Lab is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, MNPR or SLS?

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Monopar Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Monopar Therapeutics N/A N/A -$13.72M -$2.17 N/A SELLAS Life Sciences Group N/A N/A -$26.86M -$0.21 N/A

Is MNPR or SLS more profitable?

Monopar Therapeutics' return on equity of -13.08% beat SELLAS Life Sciences Group's return on equity. Company Net Margins Return on Equity Return on Assets Monopar Therapeutics N/A -13.08% -12.79% SELLAS Life Sciences Group N/A -35.91% -33.34%

Does the media refer more to MNPR or SLS?

In the previous week, SELLAS Life Sciences Group had 1 more articles in the media than Monopar Therapeutics. MarketBeat recorded 7 mentions for SELLAS Life Sciences Group and 6 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.61 beat SELLAS Life Sciences Group's score of 0.51 indicating that Monopar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SELLAS Life Sciences Group 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NRIX or MNPR?

In the previous week, Nurix Therapeutics had 4 more articles in the media than Monopar Therapeutics. MarketBeat recorded 10 mentions for Nurix Therapeutics and 6 mentions for Monopar Therapeutics. Nurix Therapeutics' average media sentiment score of 1.27 beat Monopar Therapeutics' score of 0.61 indicating that Nurix Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monopar Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Monopar Therapeutics (MNPR) Competitors

$111.89 -2.05 (-1.80%)

As of 08/28/2026 04:00 PM Eastern

Compare

MNPR vs. ALMS, BEAM, ZLAB, SLS, and NRIX

Should you buy Monopar Therapeutics stock or one of its competitors? Monopar Therapeutics's main competitors and comparable companies include Alumis (ALMS), Beam Therapeutics (BEAM), Zai Lab (ZLAB), SELLAS Life Sciences Group (SLS), and Nurix Therapeutics (NRIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Monopar Therapeutics compare to Alumis?

Monopar Therapeutics (NASDAQ:MNPR) and Alumis (NASDAQ:ALMS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

In the previous week, Alumis had 3 more articles in the media than Monopar Therapeutics. MarketBeat recorded 9 mentions for Alumis and 6 mentions for Monopar Therapeutics. Alumis' average media sentiment score of 1.38 beat Monopar Therapeutics' score of 0.61 indicating that Alumis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alumis	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Monopar Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. Monopar Therapeutics' return on equity of -13.08% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-13.08%	-12.79%
Alumis	-5,933.46%	-93.15%	-74.50%

1.8% of Monopar Therapeutics shares are held by institutional investors. 9.7% of Monopar Therapeutics shares are held by insiders. Comparatively, 33.7% of Alumis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Monopar Therapeutics has higher earnings, but lower revenue than Alumis. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A
Alumis	$24.05M	120.44	-$243.32M	-$3.86	N/A

Monopar Therapeutics has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, Alumis has a beta of -0.69, indicating that its share price is 169% less volatile than the broader market.

Monopar Therapeutics currently has a consensus target price of $118.67, suggesting a potential upside of 6.06%. Alumis has a consensus target price of $40.30, suggesting a potential upside of 80.07%. Given Alumis' higher probable upside, analysts clearly believe Alumis is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Alumis	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Monopar Therapeutics beats Alumis on 10 of the 16 factors compared between the two stocks.

How does Monopar Therapeutics compare to Beam Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Beam Therapeutics (NASDAQ:BEAM) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

In the previous week, Beam Therapeutics had 6 more articles in the media than Monopar Therapeutics. MarketBeat recorded 12 mentions for Beam Therapeutics and 6 mentions for Monopar Therapeutics. Beam Therapeutics' average media sentiment score of 1.07 beat Monopar Therapeutics' score of 0.61 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Monopar Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -54.75%. Monopar Therapeutics' return on equity of -13.08% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-13.08%	-12.79%
Beam Therapeutics	-54.75%	-30.71%	-24.07%

Monopar Therapeutics has higher earnings, but lower revenue than Beam Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A
Beam Therapeutics	$139.74M	21.67	-$79.99M	-$0.86	N/A

Monopar Therapeutics currently has a consensus price target of $118.67, indicating a potential upside of 6.06%. Beam Therapeutics has a consensus price target of $49.00, indicating a potential upside of 67.12%. Given Beam Therapeutics' higher probable upside, analysts plainly believe Beam Therapeutics is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Monopar Therapeutics has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market.

1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 9.7% of Monopar Therapeutics shares are held by insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Beam Therapeutics beats Monopar Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Monopar Therapeutics compare to Zai Lab?

Monopar Therapeutics (NASDAQ:MNPR) and Zai Lab (NASDAQ:ZLAB) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Monopar Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market. Comparatively, Zai Lab has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 9.7% of Monopar Therapeutics shares are held by insiders. Comparatively, 4.9% of Zai Lab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Monopar Therapeutics had 2 more articles in the media than Zai Lab. MarketBeat recorded 6 mentions for Monopar Therapeutics and 4 mentions for Zai Lab. Zai Lab's average media sentiment score of 0.70 beat Monopar Therapeutics' score of 0.61 indicating that Zai Lab is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Monopar Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Monopar Therapeutics' return on equity of -13.08% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-13.08%	-12.79%
Zai Lab	-41.86%	-27.43%	-16.72%

Monopar Therapeutics presently has a consensus target price of $118.67, indicating a potential upside of 6.06%. Zai Lab has a consensus target price of $37.25, indicating a potential upside of 42.83%. Given Zai Lab's higher probable upside, analysts plainly believe Zai Lab is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Monopar Therapeutics has higher earnings, but lower revenue than Zai Lab. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A
Zai Lab	$460.16M	6.45	-$175.54M	-$1.71	N/A

Summary

Monopar Therapeutics beats Zai Lab on 10 of the 16 factors compared between the two stocks.

How does Monopar Therapeutics compare to SELLAS Life Sciences Group?

Monopar Therapeutics (NASDAQ:MNPR) and SELLAS Life Sciences Group (NASDAQ:SLS) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

In the previous week, SELLAS Life Sciences Group had 1 more articles in the media than Monopar Therapeutics. MarketBeat recorded 7 mentions for SELLAS Life Sciences Group and 6 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 0.61 beat SELLAS Life Sciences Group's score of 0.51 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SELLAS Life Sciences Group	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Monopar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.21	N/A

Monopar Therapeutics' return on equity of -13.08% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-13.08%	-12.79%
SELLAS Life Sciences Group	N/A	-35.91%	-33.34%

Monopar Therapeutics has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.48, meaning that its share price is 148% more volatile than the broader market.

1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 9.7% of Monopar Therapeutics shares are held by insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Monopar Therapeutics currently has a consensus target price of $118.67, suggesting a potential upside of 6.06%. SELLAS Life Sciences Group has a consensus target price of $10.00, suggesting a potential downside of 24.30%. Given Monopar Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Monopar Therapeutics is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Monopar Therapeutics beats SELLAS Life Sciences Group on 10 of the 14 factors compared between the two stocks.

How does Monopar Therapeutics compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Monopar Therapeutics (NASDAQ:MNPR) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Monopar Therapeutics has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Monopar Therapeutics' return on equity of -13.08% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Monopar Therapeutics	N/A	-13.08%	-12.79%

Nurix Therapeutics currently has a consensus target price of $34.21, suggesting a potential upside of 30.54%. Monopar Therapeutics has a consensus target price of $118.67, suggesting a potential upside of 6.06%. Given Nurix Therapeutics' higher probable upside, equities analysts clearly believe Nurix Therapeutics is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

1.8% of Monopar Therapeutics shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by insiders. Comparatively, 9.7% of Monopar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Nurix Therapeutics had 4 more articles in the media than Monopar Therapeutics. MarketBeat recorded 10 mentions for Nurix Therapeutics and 6 mentions for Monopar Therapeutics. Nurix Therapeutics' average media sentiment score of 1.27 beat Monopar Therapeutics' score of 0.61 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monopar Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nurix Therapeutics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market.

Monopar Therapeutics has lower revenue, but higher earnings than Nurix Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	32.39	-$264.46M	-$3.45	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A

Summary

Monopar Therapeutics beats Nurix Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Monopar Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MNPR vs. The Competition

Export

Metric	Monopar Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$751.03M	$3.93B	$7.20B	$12.91B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-51.56	11.62	273.16	25.45
Price / Sales	N/A	1,357.44	634.19	94.29
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	5.74	16.53	12.98	6.14
Net Income	-$13.72M	-$22.80M	$3.48B	$348.86M
7 Day Performance	3.87%	-0.31%	0.13%	-0.80%
1 Month Performance	-2.42%	9.80%	7.08%	4.13%
1 Year Performance	227.64%	55.66%	24.67%	15.17%

Monopar Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MNPR Monopar Therapeutics	2.1214 of 5 stars	$111.89 -1.8%	$118.67 +6.1%	+227.6%	$751.03M	N/A	N/A	10	Insider Trade
ALMS Alumis	3.1578 of 5 stars	$23.96 +4.0%	$40.30 +68.2%	+382.3%	$2.98B	$24.05M	N/A	N/A	Positive News
BEAM Beam Therapeutics	2.2714 of 5 stars	$31.03 +9.5%	$49.00 +57.9%	+79.2%	$2.93B	$139.74M	N/A	510	News Coverage Positive News Analyst Forecast Gap Down
ZLAB Zai Lab	2.8116 of 5 stars	$26.17 +2.1%	$37.25 +42.3%	-21.2%	$2.92B	$460.16M	N/A	1,784
SLS SELLAS Life Sciences Group	0.3219 of 5 stars	$14.09 -1.6%	$10.00 -29.0%	+588.0%	$2.89B	N/A	N/A	10	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MNPR) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Monopar Therapeutics (MNPR) Competitors

MNPR vs. ALMS, BEAM, ZLAB, SLS, and NRIX

How does Monopar Therapeutics compare to Alumis?

Summary

How does Monopar Therapeutics compare to Beam Therapeutics?

Summary

How does Monopar Therapeutics compare to Zai Lab?

Summary

How does Monopar Therapeutics compare to SELLAS Life Sciences Group?

Summary

How does Monopar Therapeutics compare to Nurix Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNPR vs. The Competition

Monopar Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Monopar Therapeutics (MNPR) Competitors

MNPR vs. ALMS, BEAM, ZLAB, SLS, and NRIX

How does Monopar Therapeutics compare to Alumis?

Does the media refer more to MNPR or ALMS?

Is MNPR or ALMS more profitable?

Do institutionals and insiders hold more shares of MNPR or ALMS?

Which has preferable earnings & valuation, MNPR or ALMS?

Which has more risk and volatility, MNPR or ALMS?

Do analysts prefer MNPR or ALMS?

Summary

How does Monopar Therapeutics compare to Beam Therapeutics?

Does the media favor MNPR or BEAM?

Is MNPR or BEAM more profitable?

Which has preferable earnings and valuation, MNPR or BEAM?

Do analysts recommend MNPR or BEAM?

Which has more risk & volatility, MNPR or BEAM?

Do insiders and institutionals have more ownership in MNPR or BEAM?

Summary

How does Monopar Therapeutics compare to Zai Lab?

Which has more risk & volatility, MNPR or ZLAB?

Do institutionals & insiders have more ownership in MNPR or ZLAB?

Does the media refer more to MNPR or ZLAB?

Is MNPR or ZLAB more profitable?

Do analysts recommend MNPR or ZLAB?

Which has higher valuation & earnings, MNPR or ZLAB?

Summary

How does Monopar Therapeutics compare to SELLAS Life Sciences Group?

Does the media refer more to MNPR or SLS?

Which has stronger valuation & earnings, MNPR or SLS?

Is MNPR or SLS more profitable?

Which has more risk and volatility, MNPR or SLS?

Do institutionals and insiders hold more shares of MNPR or SLS?

Do analysts recommend MNPR or SLS?

Summary

How does Monopar Therapeutics compare to Nurix Therapeutics?

Is NRIX or MNPR more profitable?

Do analysts recommend NRIX or MNPR?

Do institutionals & insiders hold more shares of NRIX or MNPR?

Does the media refer more to NRIX or MNPR?

Which has more risk and volatility, NRIX or MNPR?

Which has stronger valuation and earnings, NRIX or MNPR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNPR vs. The Competition

Monopar Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools